Rediscovery Life Sciences has executed an exclusive license with The Medical University of South Carolina (MUSC) to develop suramin in acute kidney injury (AKI). First introduced in 1922 to treat African sleeping sickness, suramin has never been approved in the U.S. Researchers at Dr. Rick Schnellman’s laboratory at MUSC demonstrated, in a range of animal models, that suramin reduces neutrophil infiltration and other inflamm...
Rediscovery Life Sciences has executed an exclusive license with The Medical University of South Carolina (MUSC) to develop suramin in acute kidney injury (AKI). First introduced in 1922 to treat African sleeping sickness, suramin has never been approved in the U.S. Researchers at Dr. Rick Schnellman’s laboratory at MUSC demonstrated, in a range of animal models, that suramin reduces neutrophil infiltration and other inflammatory cells, blocks apoptosis of renal tubular epithelium and stimulates reparative processes in injured kidneys.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.